Saturday 17 October 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.02
0.01
−0.97%
Follow COCP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(94.94%) | (111.40%) | (154.62%) | (311.68%) | |
| (72.50%) | (76.23%) | (97.64%) | (151.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(131.26%) | (146.77%) | (232.89%) | (1,442.38%) | |
Average Days of Receivables |
0.00 | 0.00 | 156.22 | 202.14 | |
Free Cash Flow per Share |
(0.88) | (0.73) | (0.55) | (0.58) | |
Free Cash Flow |
(9.63) | (8.20) | (7.59) | (7.95) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
| Other line items | |||||
Cash ROIC |
(62.22%) | (61.08%) | (85.55%) | (241.91%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 1.61 | 1.12 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 284.93% | 457.94% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 235.83% | 327.61% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 15.30% | 21.07% | |
Operating CF/Net income |
0.99 | 0.93 | 0.86 | 0.80 | |
Depreciation/Fixed assets |
3.64 | 4.04 | 4.48 | 5.29 | |
Capex/Depreciation |
(0.03) | (0.03) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.13 | 0.10 | |
Operating CF per Share |
(0.87) | (0.73) | (0.55) | (0.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates